7sf5 - Revision history

OCA at 16:50, 18 October 2023

OCA — Wed, 18 Oct 2023 16:50:26 GMT

←Older revision		Revision as of 16:50, 18 October 2023
Line 1:		Line 1:

	==M. tb EgtD in complex with HD3==		==M. tb EgtD in complex with HD3==
-	<StructureSection load='7sf5' size='340' side='right'caption='[[7sf5]]' scene=''>	+	<StructureSection load='7sf5' size='340' side='right'caption='[[7sf5]], [[Resolution\|resolution]] 2.52Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7SF5 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7SF5 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[7sf5]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Mycobacterium_tuberculosis Mycobacterium tuberculosis]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7SF5 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7SF5 FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7sf5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7sf5 OCA], [https://pdbe.org/7sf5 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7sf5 RCSB], [https://www.ebi.ac.uk/pdbsum/7sf5 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7sf5 ProSAT]</span></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.52Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=95I:N-(benzylcarbamothioyl)-L-histidine'>95I</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7sf5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7sf5 OCA], [https://pdbe.org/7sf5 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7sf5 RCSB], [https://www.ebi.ac.uk/pdbsum/7sf5 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7sf5 ProSAT]</span></td></tr>
	</table>		</table>
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/EGTD_MYCTU EGTD_MYCTU] Catalyzes the SAM-dependent triple methylation of the alpha-amino group of histidine to form hercynine, a step in the biosynthesis pathway of ergothioneine.[UniProtKB:A0R5M8]
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Ergothioneine (EGT) is a low molecular weight histidine betaine essential in all domains of life but only synthesized by selected few organisms. Synthesis of EGT by Mycobacterium tuberculosis (M. tb) is critical for maintaining bioenergetic homeostasis and protecting the bacterium from alkylating agents, oxidative stress, and anti-tubercular drugs. EgtD, an S-adenosylmethionine-dependent methyltransferase (AdoMet), catalyzes the trimethylation of L-Histidine to initiate EGT biosynthesis and this reaction has been shown to be essential for EGT production in mycobacteria and for long-term infection of murine macrophages by M. tb. In this work, library screening and structure-guided strategies identified multiple classes of M. tb EgtD inhibitors that bind in various regions of the enzyme active site. X-ray crystal structures of EgtD-inhibitor complexes confirm that L-Histidine analogs bind solely to the L-Histidine binding site while drug-like inhibitors, such as TGX-221, and S-Glycyl-H-1152 span both the L-Histidine and AdoMet binding sites. These enzyme-inhibitor complexes provide detailed structural information of compound scaffolds useful for developing more potent inhibitors that could shorten Tuberculosis treatment regimens by weakening important bacterial defenses.
		+
		+	Inhibitors of Mycobacterium tuberculosis EgtD target both substrate binding sites to limit hercynine production.,Sudasinghe TD, Banco MT, Ronning DR Sci Rep. 2021 Nov 15;11(1):22240. doi: 10.1038/s41598-021-01526-6. PMID:34782676<ref>PMID:34782676</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 7sf5" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
	[[Category: Large Structures]]		[[Category: Large Structures]]
		+	[[Category: Mycobacterium tuberculosis]]
	[[Category: Ronning DR]]		[[Category: Ronning DR]]
	[[Category: Sudasinghe TD]]		[[Category: Sudasinghe TD]]

OCA at 06:22, 1 December 2021

OCA — Wed, 01 Dec 2021 06:22:44 GMT

←Older revision		Revision as of 06:22, 1 December 2021
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 7sf5 ~~is ON HOLD until Paper Publication~~	+	==M. tb EgtD in complex with HD3==
-		+	<StructureSection load='7sf5' size='340' side='right'caption='[[7sf5]]' scene=''>
-	~~Authors~~: ~~Sudasinghe~~, T.D., ~~Ronning~~, D.R.	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7SF5 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7SF5 FirstGlance]. <br>
-	~~Description~~: M. ~~tb EgtD in complex with HD3~~	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7sf5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7sf5 OCA], [https://pdbe.org/7sf5 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7sf5 RCSB], [https://www.ebi.ac.uk/pdbsum/7sf5 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7sf5 ProSAT]</span></td></tr>
-	[[Category: ~~Unreleased~~ Structures]]	+	</table>
-	[[Category: Ronning~~, D.R~~]]	+	__TOC__
-	[[Category: Sudasinghe~~, T.D~~]]	+	</StructureSection>
		+	[[Category: Large Structures]]
		+	[[Category: Ronning DR]]
		+	[[Category: Sudasinghe TD]]

OCA at 05:14, 10 November 2021

OCA — Wed, 10 Nov 2021 05:14:39 GMT

←Older revision		Revision as of 05:14, 10 November 2021
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 7sf5 is ON HOLD	+	The entry 7sf5 is ON HOLD until Paper Publication

	Authors: Sudasinghe, T.D., Ronning, D.R.		Authors: Sudasinghe, T.D., Ronning, D.R.
Line 7:		Line 7:
	Description: M. tb EgtD in complex with HD3		Description: M. tb EgtD in complex with HD3
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
-	[[Category: Sudasinghe, T.D]]
	[[Category: Ronning, D.R]]		[[Category: Ronning, D.R]]
		+	[[Category: Sudasinghe, T.D]]

OCA: Protected "7sf5" [edit=sysop:move=sysop]

OCA — Wed, 13 Oct 2021 10:25:57 GMT

Protected "7sf5" [edit=sysop:move=sysop]

←Older revision

Revision as of 10:25, 13 October 2021

OCA: New page: '''Unreleased structure''' The entry 7sf5 is ON HOLD Authors: Sudasinghe, T.D., Ronning, D.R. Description: M. tb EgtD in complex with HD3 Category: Unreleased Structures [[Category...

OCA — Wed, 13 Oct 2021 10:25:56 GMT

New page: '''Unreleased structure''' The entry 7sf5 is ON HOLD Authors: Sudasinghe, T.D., Ronning, D.R. Description: M. tb EgtD in complex with HD3 Category: Unreleased Structures [[Category...

New page

'''Unreleased structure'''

The entry 7sf5 is ON HOLD

Authors: Sudasinghe, T.D., Ronning, D.R.

Description: M. tb EgtD in complex with HD3
[[Category: Unreleased Structures]]
[[Category: Sudasinghe, T.D]]
[[Category: Ronning, D.R]]